Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Design Therapeutics Inc (NQ: DSGN )

5.500 -0.280 (-4.84%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 28, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 306,805
Open 5.800
Bid (Size) 5.490 (26)
Ask (Size) 5.500 (2)
Prev. Close 5.780
Today's Range 5.490 - 5.960
52wk Range 5.580 - 26.30
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Short Squeeze Stocks: BBBY, SI and 3 Other Stocks Ready to Squeeze
Short squeeze stocks are all over Wall Street in the wake of the regional banking crisis. Which names should you keep an eye out for? 
Via InvestorPlace
Short Interest Update - Monday, March 27
Although equities broadly are starting the new week higher, the most heavily shorted stocks are trading lower today. 
Via Talk Markets

Performance

YTD
-43.71%
-43.71%
1 Month
-21.76%
-21.76%
3 Month
-40.15%
-40.15%
6 Month
-63.31%
-63.31%
1 Year
-65.65%
-65.65%

More News

Read More
Why Baidu Shares Are Trading Higher By More Than 6%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Via Benzinga
First Republic Bank, Blend Labs, Purple Innovation And Other Big Stocks Moving Lower On Friday
Via Benzinga
Design Therapeutics Highlights Pipeline Progress and Reports Fourth Quarter and Full Year 2022 Financial Results
From Design Therapeutics, Inc.
Via Globe NewsWire
Illumina, Seagen And Other Big Stocks Moving Higher On Monday
Via Benzinga
Design Therapeutics, Inc. (NASDAQ:DSGN) Investor Alert: Investigation Concerning Possible Wrongdoing
Via SBWire
Stocks That Hit 52-Week Lows On Wednesday
Via Benzinga
Stocks That Hit 52-Week Lows On Tuesday
Via Benzinga
Stocks That Hit 52-Week Lows On Monday
Via Benzinga
Design Therapeutics to Participate in the SVB Securities Virtual Global Biopharma Conference
From Design Therapeutics, Inc.
Via Globe NewsWire
Design Therapeutics, Inc. (NASDAQ:DSGN) Shareholder Notice: Investigation over Possible Violations of Securities Laws
Via SBWire
DESIGN ALERT: Bragar Eagel & Squire, P.C. is Investigating Design Therapeutics, Inc. on Behalf of Design Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via Globe NewsWire
MillerKnoll, Cleveland-Cliffs And Some Other Big Stocks Moving Higher On Thursday
Via Benzinga
$7.5 Million Bet On This Biotechnology Stock? Check Out These 3 Stocks Insiders Are Buying
Via Benzinga
S&P 500 Rises 0.5%; Ciena Posts Upbeat Q4 Results
Via Benzinga
Why Express Shares Are Trading Higher By 39%? Here Are 50 Stocks Moving In Thursday's Mid-Day Session
Via Benzinga
Nasdaq Gains 100 Points; Rent the Runway Shares Spike Higher
Via Benzinga
Chefs' Warehouse, Chart Industries And Some Other Big Stocks Moving Lower On Thursday
Via Benzinga
Dow Rises 150 Points; US Jobless Claims Increase To 230,000
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
Via InvestorPlace
Design Therapeutics Reports Positive Data from Single-Ascending Dose Trial of DT-216 for the Treatment of Friedreich Ataxia and Portfolio Progress
From Design Therapeutics, Inc.
Via Globe NewsWire
Foot Locker, Ross Stores, Palo Alto Networks, And Other Big Gainers From Friday
Via Benzinga
Design Therapeutics Highlights Pipeline Progress and Upcoming Milestones and Reports Third Quarter 2022 Financial Results
From Design Therapeutics, Inc.
Via Globe NewsWire
Design Therapeutics to Present Preclinical Data Highlighting the Potential of its GeneTAC™ Small Molecule, DT-216, for the Treatment of Friedreich Ataxia at ICAR 2022
From Design Therapeutics, Inc.
Via Globe NewsWire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.